About Avenzo Therapeutics
Avenzo Therapeutics is a private company based in San Diego, California, incorporated in 2022 in Delaware. It has reported $433,080,791 raised in two offerings on Form D since September 2022.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 22, 2025 | Sep 5, 2025 | $47,230,787of $75.0M target | 20 | $2.3M | EquityRule 506(b) | Form D ↗ |
| Sep 14, 2022 | Sep 29, 2022amended Nov 20, 2024 | $385,850,004fully sold | 22 | $17.5M | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Total, two offerings | $433,080,791 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Avenzo Therapeutics's Form D filed Sep 5, 2025.
CG
Carl Gordon
Director
Also a director at ADARx Pharmaceuticals, BlossomHill Therapeutics and Garuda Therapeutics.
GN
Garry Nicholson
Director
PM
JL
PT
Paolo Tombesi
Executive officer
MH
Mohammad Hirmand
Executive officer
SG
SL
Scott Lipman
Executive officer
AC
Athena Countouriotis
Executive officer and director
BS
Brian Sun
Executive officer
JA
Jakob Dupont, M.D., M.A.
Director